Ligand Pharmaceuticals

LGND

Market cap $3.87B

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002 Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate $1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor Day in New York City today.

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based business model.

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable assets under management at quarter-end.

Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a key driver of its outperformance and future investment appeal. This article evaluates LGND's ongoing investment prospects in light of its recent substantial price appreciation.

Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.

Third quarter performance driven by strong portfolio royalty revenue growth of  47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share 1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.

Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asset Management & Custody Banks) saw another quarter of better-than-expected flows, driving earnings upside relative to expectations. SI-Bone (SIBN) (Health Care, Health Care Equipment) was weaker despite reporting a marginal beat on revenue and expectations of improved profitability.

JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025.